Introduction {#S1}
============

Arrhythmogenic cardiomyopathy (ACM) is a primary heritable disease of the myocardium, clinically characterized by increased risk of ventricular arrhythmias and sudden cardiac death (SCD) ([@B141]).

ACM includes arrhythmogenic right ventricular cardiomyopathy (ARVC), which affects the right ventricle (RV); left dominant arrhythmogenic cardiomyopathy (LD-ACM), in which the left ventricle is the first chamber to be affected; and biventricular ACM ([@B125]; [@B92]).

The histological feature of ACM is the progressive replacement of the myocardium with fibrotic or fibrofatty tissue, typically starting from the epicardium ([@B75]; [@B6]).

Three main etiopathogenetic theories have been proposed to explain the origin and development of the ACM phenotype: ([@B9]; [@B141]) the dysontogenetic (dysplasia) theory considers ACM as a developmental disorder of the RV ([@B84]; [@B125]), the myocarditis theory based on the evidence of inflammation in ACM hearts ([@B9]; [@B18]; [@B92]; [@B113]) and the dystrophic theory, based on the histopathological similarities between ACM and skeletal muscle dystrophies (SMDs) ([@B108]; [@B51]; [@B75]; [@B6]). According to the dysontogenetic theory, the disease was interpreted as a congenital defect of the development of the right ventricular myocardium and hence called "right ventricular dysplasia" ([@B84]). Later on, evidence from genetic, morphological, and clinical studies showed that ACM was not a structural defect present at birth but a genetic progressive disease of the myocardium, associated with a high risk of life-threatening arrhythmias ([@B9], [@B7], [@B6]). For this reason, the term dysplasia was replaced, and the condition became known as "arrhythmogenic RV cardiomyopathy," and the disease was listed, together with hypertrophic, restrictive, and dilated variants, in the WHO classification of cardiomyopathies in 1995 ([@B118]).

Although ACM is a cardiac pathology while SMD affects mainly the skeletal muscle, the two diseases share histological features as well as molecular and cellular pathogenic mechanisms.

ACM and SMD are both genetically transmitted and show similar histopathological hallmarks, namely muscle degeneration, inflammation, and tissue replacement by fibrosis and fat.

Myocardium loss in ACM is the consequence of myocyte death by apoptosis and/or necrosis, which is accompanied by inflammation followed by abnormal fibrofatty repair ([@B9], [@B6]; [@B111]). Similarly, muscle degeneration, inflammation, fat infiltration, and fibrosis have been detected in the muscles of patients and mouse models of SMD, mainly in Duchenne muscle dystrophy (DMD) ([@B108]; [@B51]; [@B101]; [@B27]).

Inflammation is a key feature of both diseases and precedes the fibrofatty infiltration ([@B9]; [@B75]). Nevertheless, whether inflammation plays a primary role or is a secondary response to cell death remains elusive.

Although the primary presenting symptom in SMDs is skeletal muscle weakness, cardiac muscle may also be similarly affected. Indeed, cardiomyopathies are an increasingly recognized manifestation of SMDs and contribute significantly to the morbidity and mortality ([@B62]).

DMD is the most common form of SMD. DMD is inherited in a X-linked recessive manner and is caused by out-of-frame mutations, which result in the absence of functional dystrophin protein. Becker muscular dystrophy (BMD) is another X-linked muscular dystrophy showing a milder clinical course than DMD. BMD is also caused by mutations in the *DMD* gene, but mutations in BMD tend to be in-frame and result in abnormal and less functional dystrophin instead than in the complete absence of the protein ([@B94]; [@B62]). Research over the last 20 years has significantly advanced our knowledge of the etiology and pathogenesis of both ACM and SMD. Two main pathways, the Wnt signaling and the Hippo pathway, are affected in both diseases ([@B41]; [@B73]; [@B25]). Furthermore, the heart and skeletal muscle contain a subset of analogous resident mesenchymal progenitor cells, identified by the surface marker platelet-derived growth factor receptor alpha (PDGFRA) and called fibroadipocyte progenitors, which, in the presence of chronic myocyte injury induced by the causal mutation, differentiate to adipocytes and fibroblasts ([@B143], [@B144]; [@B47]; [@B72]; [@B82]).

This review describes similarities in genetics, histology/imaging features, and pathogenic mechanisms between ACM and SMD.

Genetics {#S1.SS1}
--------

Despite that the familial background of ACM was known from late 1980s ([@B98], [@B97]), the first causal mutation was identified 20 years later in a rare recessive syndrome known as Naxos disease, characterized by typical ARVC associated with wooly hair and palmoplantar keratoderma ([@B88]). The mutation was a 2 bp deletion in the gene encoding for plakoglobin (*JUP*) ([@B88]), a protein of the desmosomes and adherens junctions, which are part of a more complex functional unit, responsible for structural integrity and synchronized contraction of the cardiac tissue, named intercalated disk (ID). IDs include, in addition to desmosomes, several other specialized structures, mainly fascia adherens and gap junctions ([@B128]; [@B132]). Desmosomes are complex structures not only responsible for cell-cell attachment but also regulators of signaling pathways ([@B132]).

After the discovery of *JUP* gene, additional causal autosomal dominant mutations were identified in desmosome genes, such as plakophilin-2 (*PKP2*) ([@B44]; [@B32]), desmoplakin (*DSP*) ([@B117]), desmoglein-2 (*DSG2*) ([@B110]; [@B43]), and desmocollin-2 (*DSC2*) ([@B133]); in addition, ACM autosomal dominant forms due to *JUP* ([@B30]) and recessive forms due to *DSP* ([@B100]) and *DSC2* ([@B1]) mutations have been identified, usually in the context of cardiocutaneous syndromes. Mutations in desmosomal genes are identified in approximately two-thirds of the affected probands; hence ACM is commonly considered a disease of the desmosomes.

ACM mutations have also been identified in non-desmosomal genes encoding for adherens junction components such as catenin-α3 and cadherin 2 ([@B148]; [@B87]; [@B142]); nuclear lamina proteins lamin A/C (*LMNA*) ([@B116]) and transmembrane protein 43 (*TMEM43*) ([@B91]); cytoskeletal proteins desmin (*DES*) ([@B151]; [@B66]; [@B12]) and filamin C (*FLNC*) ([@B102]; [@B54]; [@B13]); the sarcomere protein titin (*TTN*) ([@B135]); ion channels such as phospholamban (*PLN*) ([@B146], [@B147]; [@B145]), ryanodine receptor 2 (*RYR2*) ([@B140]), and sodium voltage-gated channel alpha subunit 5 (SCN5A) ([@B136]); and transforming growth factor β3 (*TGFB3*) ([@B11]; [Table 1](#T1){ref-type="table"}).

###### 

List of causal genes for ACM.

  **Gene**                   **Encoded protein**             **Estimated frequency (%)**   **Features**                                                                                                                          **Mode of inheritance**   **References**
  -------------------------- ------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -----------------------------------------------------
  **Desmosome**                                                                                                                                                                                                                                            
  *PKP2*                     Plakophilin 2                   ∼40                           Haploinsufficiency; ACM                                                                                                               AD, AR                    [@B98], [@B97]
  *DSP*                      Desmoplakin                     ∼16                           Associated with LV-dominant disease; Carvajal syndrome                                                                                AD, AR                    [@B88]; [@B117]
  *DSG2*                     Desmoglein 2                    ∼10                           Overlap with DCM                                                                                                                      AD                        [@B128]; [@B132]
  *DSC2*                     Desmocollin 2                   ∼8                            ACM                                                                                                                                   AD, AR                    [@B44]; [@B110]
  *JUP*                      Junction plakoglobin            Rare                          Naxos disease; autosomal dominant ACM                                                                                                 AD, AR                    [@B32]; [@B60]
  **Adherens junction**                                                                                                                                                                                                                                    
  *CTNNA3*                   Catenin-α3                      Rare                          Incomplete penetrance; normal plakoglobin localization                                                                                AD                        [@B43]
  *CDH2*                     Cadherin 2                      Rare                          No specific genotype--phenotype relationship identified                                                                               AD                        [@B30]; [@B133]
  **Nucleus/Cytoskeleton**                                                                                                                                                                                                                                 
  *LMNA*                     Lamin A/C                       Rare                          DCM phenotype, conduction defects, arrhythmias and high risk of sudden cardiac death; muscle dystrophies; lipodystrophies; progeria   --                        [@B100]; [@B136]
  *TMEM43*                   Transmembrane protein 43        Rare                          Fully penetrant; affected men more severely than women; LV involvement; muscle dystrophy                                              AD                        [@B1]
  *DES*                      Desmin                          Rare                          Fully penetrant; associated with LV and RV-dominant ACM, DCM and skeletal myopathies                                                  AD                        [@B140]; [@B148]; [@B147]; [@B145]; [@B87]; [@B142]
  *FLNC*                     Filamin C                       Rare                          Associated with Left-dominant ACM, high risk of arrhythmias and sudden death                                                          --                        [@B91]; [@B66]; [@B116]
  **Sarcomere**                                                                                                                                                                                                                                            
  *TTN*                      Titin                           Rare                          Higher risk of supraventricular tachycardia and progression to heart failure; tibial muscular dystrophy                               --                        [@B151]
  **Ion transport**                                                                                                                                                                                                                                        
  *PLN*                      Phospholamban                   Rare                          Low prevalent and cause DCM and ACM                                                                                                   --                        [@B102]; [@B12]; [@B54]
  *RYR2*                     Ryanodine receptor 2            Rare                          Overlap with DCM                                                                                                                      AD                        [@B13]
  *SCN5A*                    Nav1.5                          Rare                          Prolonged QRS interval                                                                                                                --                        [@B135]
  **Cytokines**                                                                                                                                                                                                                                            
  *TGFB3*                    Transforming growth factor-β3   Rare                          No specific genotype--phenotype relationship identified                                                                               --                        [@B146]

AD, autosomal dominant; AR, autosomal recessive; ACM, Arrhythmogenic cardiomyopathy; DCM, Dilatative Cardiomyopathy; LV, left ventricle; RV, right ventricle; SCN5A, Sodium Voltage-Gated Channel Alpha Subunit 5; Nav1.5, α-subunit of the cardiac sodium channel complex.

Interestingly, *DES* ([@B89]; [@B150]; [@B55]), *LMNA* ([@B19]; [@B116]), *TMEM43* ([@B91]; [@B70]; [@B96]), and *TTN* ([@B50], [@B49]; [@B112]; [@B135]; [@B93]) have been associated with either cardiomyopathies or SMD. Hence, patients with primary myopathy due to a mutation in one of these genes should be screened for cardiac involvement.

Desmin is the main intermediate filament and is highly expressed in both skeletal and cardiac muscle cells; therefore, *DES* mutations frequently cause concomitant skeletal-muscle and cardiac phenotype ([@B150]).

Mutations in the *LMNA* gene, encoding lamin A and lamin C, cause a wide range of diseases: Emery-Dreifuss muscular dystrophy (EDMD) types 2 and 3, limb girdle muscular dystrophy (LGMD) type 1B, cardiomyopathy, lipodystrophies, peripheral neuropathies, and progeria syndromes. These diseases are collectively known as laminopathies ([@B19]). Conduction disorders, atrial fibrillation, ventricular tachycardia, and increased risk of sudden cardiac death are typical features of LMNA-associated cardiomyopathies. Mutations in *TMEM43* may cause ACM and EDMD ([@B91]; [@B70]; [@B96]). It is not clear how defects in these nuclear membrane proteins result in the phenotype development; possibly, the mutant proteins may increase mechanical stress to the nucleus or alter gene expression through interaction with the chromatin ([@B26]; [@B23]).

*TTN* mutations cause different skeletal phenotypes (such as tibial muscular dystrophy, LGMD type 2J, EDMD, hereditary myopathy with early respiratory failure, central core myopathy, centronuclear myopathy), collectively known as titinopathies. The severity of the myopathy and the cardiac involvement in titinopathies are determined by the position and type of *TTN* mutation ([@B49]; [@B93]). Moreover, some *TTN* mutations cause isolated cardiomyopathy, mainly DCM but also HCM or ACM, without skeletal muscle involvement ([@B135]; [@B93]).

DMD and BMD are caused by mutations in the gene encoding dystrophin, a rod-shaped cytoplasmic protein, which is part of the dystroglycan complex (DGC), the multimeric complex that forms a structural link between the filamentous (F)-actin cytoskeleton and the extracellular matrix (ECM) in both cardiac and skeletal muscle and provides mechanical support to the skeletal or cardiac plasma membrane during contraction ([@B35]; [@B121]). It has been shown that the specific dystrophin mutations affect the incidence and severity of cardiomyopathy and response to treatment ([@B59]).

Histological Features and Inflammation {#S1.SS2}
--------------------------------------

ACM and SMD share similar histopathological features consisting of progressive muscular degeneration due to apoptosis or necrosis, inflammatory infiltrates, and fibrofatty tissue replacement ([@B108]; [@B51]; [@B9], [@B6]; [@B83]; [@B28]; [@B101]; [@B111]; [@B27]; [Figure 1](#F1){ref-type="fig"}). Interestingly, fibrosis in ACM is present not only in the form of fibrofatty infiltration but also as interstitial fibrosis, with or without adiposis ([@B8]; [@B85]).

![Hematoxylin & eosin images showing fibroadiposis in human skeletal muscle dystrophies (SMD) and in arrhythmogenic cardiomyopathy (ACM). **(A)** The pathological aspect of the skeletal muscle observed in Duchenne muscle dystrophy. **(B)** shows the typical histological aspect of the heart tissue in ACM. Panel (A) from [@B57]. Panel (B) from [@B138].](fphys-11-00834-g001){#F1}

Inflammation is a key feature of both ACM and SMD and is usually detected at the early stages of the disease before the development of fibroadiposis.

Infiltration of inflammatory cells in the heart has been found in over 70% of ARVC patients and in ACM mouse models ([@B139]; [@B9], [@B6]; [@B28]; [@B111]; [@B69]; [@B33]): patchy mononuclear inflammatory infiltrates of CD3 + T lymphocytes ([@B33]) and CD45 +; CD68 + ([@B9]; [@B33]) macrophages are observed in association with dying myocytes, suggesting that the pathological process may be immunologically mediated ([@B139]; [@B9]; [@B28]; [@B33]).

Similarly, the presence of macrophages, CD4 + and CD8 + T cells, natural killer T cells, neutrophils, and eosinophils has been described in the skeletal muscle of patients with DMD and of mdx mice, a widely used animal model of DMD ([@B2]; [@B131]; [@B130]; [@B153]; [@B78]). A recent study has shown that T lymphocytes infiltrate mdx mouse dystrophic muscles prior to the occurrence of necrosis, suggesting a primary role of this cell type in the onset of the disease. Furthermore, the same study demonstrated that inhibition of the protein kinase C θ, a key regulator of T-cell activation, markedly diminishes the size of the inflammatory cell infiltrates and reduces muscle damage ([@B78]).

Inflammation in ARVC patients has also been confirmed by detection of increased plasma levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α) ([@B18]). Similarly, DMD patients and mdx mice present with higher serum levels of inflammatory cytokines as compared with healthy subjects ([@B5]; [@B29]; [@B109]).

The empirical observation that immunosuppressive drugs, such as glucocorticoids, can improve muscle strength in patients and in animal models of DMD furthers supports a role for the immune system in the pathogenesis of the disease ([@B156]; [@B58]).

Although the presence of inflammation is widely recognized in both ACM and SMD, its origin and role as a primary event or secondary response to myocyte damage is unknown.

The role of autoimmunity as a trigger for inflammation is a new research field in both ACM and SMD. However, so far, the evidence supporting the involvement of autoimmune response in the pathogenesis of these diseases is still limited, and further studies are needed for the identification of specific molecular and cellular players.

Although the infiltration of immune cells in dystrophic muscle is viewed as a generalized inflammatory response ([@B2]; [@B131]; [@B130]; [@B153]), several studies suggest that an autoimmune T-cell-mediated response to specific ill-muscle antigens may also be involved in the pathogenesis of SMDs ([@B48]; [@B153]; [@B14]; [@B154]).

Recent deep-sequencing studies examining the T-cell receptor (TCR) repertoire of regulatory T cells (Tregs) in mdx muscle revealed an enrichment of several TCR rearrangements ([@B14]), suggesting that Tregs react to multiple self-antigens in dystrophic muscle. Thus, patients may retain a pool of dystrophin-reactive T cells, which may be further activated by expression of mutant dystrophin or dystrophin introduced exogenously by gene therapy. Indeed, the presence of an autoimmune response in muscle dystrophies was described in a clinical gene therapy trial in 2010 in which circulating antidystrophin T cells were unexpectedly detected in DMD patients before transgene delivery ([@B90]). The autoimmune response was induced by epitopes contained in the truncated dystrophin encoded by the endogenous gene after spontaneous in-frame splicing ([@B90]).

Another recent study has confirmed that a substantial number of DMD patients present with a pre-existing pool of circulating dystrophin-reactive T cells ([@B40]).

Likewise, the cause of the non-infectious myocarditis in ACM could plausibly be due to autoimmunity. Specific serum antidesmoglein-2 autoantibodies have been detected in ARVC patients regardless of the underlying mutation as compared with normal subjects and non-ARVC cardiomyopathies ([@B22]). A recent study has shown the presence of serum antiheart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) in the majority of familial and in almost half of sporadic ARVC cases, including some healthy relatives ([@B16]). Furthermore, the serum levels of these autoantibodies in affected individuals were associated with disease severity ([@B16]). The findings suggest a primary role of autoimmunity in the pathogenesis of ACM, as observed previously in primary dilated cardiomyopathy ([@B15]), and open the stage to the potential therapeutic use of immunosuppression in biopsy-proven virus-negative autoantibody-positive inflammatory ACM.

The pathobiology responsible for an autoimmune response in ACM patients is still unknown; likewise, further studies are necessary to establish to what degree autoimmunity participates in the pathophysiology of the disease. One hypothesis is that the ACM causal mutation may induce the expression of a protein with unmasked "cryptic" epitopes; alternatively, myocyte damage may lead to the release of autoantigens that stimulate the immune system to generate autoantibodies.

Longitudinal studies will eventually clarify whether AHA and AIDA may be used as biomarkers to predict the development of the disease in healthy relatives.

Non-invasive Tissue Characterization {#S1.SS3}
------------------------------------

Currently, the preferred imaging technique in both ACM and SMD is magnetic resonance imaging (MRI), which combines structural and functional evaluation with non-invasive tissue characterization ([@B106]).

Tissue characterization by MRI is mainly based on the detection of changes in proton relaxation times T1 (also known as longitudinal relaxation) and T2 (also known as transverse relaxation). T1-weighted sequences are used to identify fat infiltration and diffuse fibrosis, while T2-weighted imaging is mainly used to detect the presence of edema. Moreover, T1-weighted imaging after infusion of gadolinium, also known as late gadolinium enhancement (LGE), is used to detect focal fibrosis. In cardiology, this technique is essential in the differential diagnosis of ischemic cardiomyopathy, in which LGE is localized in an area of coronary artery distribution and always involves the subendocardial region, versus non-ischemic cardiomyopathy, in which LGE does not occur in a specific coronary artery territory and is often midwall or epicardial rather than subendocardial or transmural ([@B106]). Moreover, from the LGE distribution patterns, it is possible to make an etiological diagnosis ([@B68]; [@B107]).

Cardiac MRI has an important role in the clinical management of ACM because it allows the identification of minor tissue abnormalities, before the onset of morphofunctional abnormalities observed by echocardiography ([@B126], [@B125]; [@B124]). Furthermore, it has been shown that LGE distribution pattern differs among ACM subtypes and between carriers of desmosomal versus non-desmosomal pathogenic variants ([@B126]; [@B124]; [@B123]). Septal LGE is present in \> 50% of cases of LD-ACM, unlike ARVC in which septal involvement is rare ([@B125]). Furthermore, ACM patients with non-desmosomal variants usually show a circumferential subepicardial LV-LGE pattern, while those with desmosomal variants are more likely to have RV-LGE ([@B123]).

Tissue characterization of skeletal muscle by MRI has an important role in disease staging and evaluation of therapeutic response for a number of neuromuscular diseases, including DMD ([@B38]). T1-weighted imaging in the skeletal muscle of DMD patients shows higher T1 values at the early stages of the disease, which go down with increasing fatty replacement and clinical deterioration ([@B86]; [@B38]). Moreover, it has been shown that the mean T2 relaxation time of thigh muscles in DMD correlates significantly with the mean fat fraction ([@B162]) and the severity of muscle weakness ([@B64]).

Gadolinium, which in normal muscle remains extracellular, is taken up into the muscle fibers with damaged membranes ([@B137]). Hence, because dystrophin deficiency renders muscle fibers susceptible to contraction-induced injury, a higher amount of gadolinium uptake has been found in the muscles of DMD patients after stepping exercise as compared with controls ([@B42]).

It is known that patients with dystrophinopathies may develop dilated cardiomyopathy. Cardiac MRI provides accurate assessments of left ventricular size and function in patients with DMD and BMD ([@B52]). Cardiac MRI, with the use of strain technique, allows to identify cardiac involvement in the early stages, before the evidence of functional impairment at the echocardiography. The presence of LGE in the dystrophic heart is a sensitive early detection tool, as it usually precedes LV systolic dysfunction; moreover, the extent of fibrosis has been associated with an increased risk of progression toward ventricular dysfunction and increased mortality ([@B129]; [@B107]). DMD and BMD patients with associated cardiomyopathy present a characteristic non-ischemic LGE pattern localized in the posterobasal region of the left ventricle, which starts from the subepicardium. Over the years, with the deterioration of the cardiac dysfunction, the LGE extends toward transmurality and to other myocardial segments (i.e., septum) ([@B114]); the late involvement of the septum differentiate the DMD cardiomyopathy from left-sided ACM, in which the septum is already affected in the early stages of the disease.

Pathogenic Molecular Pathways {#S1.SS4}
-----------------------------

Mutations in desmosomal genes account for about two-thirds of ACM cases ([@B75]; [@B6]). Thus, ACM is considered a disease of desmosomes, structures responsible not only for myocytes-myocyte attachment but also hubs of molecular pathways regulated at the cell junctions. Indeed, it has been shown that desmosomal proteins are not only structural proteins but have also signaling functions as they regulate cellular proliferation, differentiation, apoptosis, and gene expression ([@B41]; [@B10]; [@B75]; [@B31]; [@B73]; [@B25]; [@B47]; [@B149]).

Animal and cellular models indicate abnormal biomechanical properties, and crosstalks from the desmosome to the cytoskeleton, nucleus, gap junctions, and ion channels are implicated in the pathobiology of ACM ([@B41]; [@B10]; [@B75]; [@B31]; [@B73]; [@B25]; [@B47]; [@B149]; [@B115]).

Fibrofatty infiltration is a common feature of SMD and ACM ([@B108]; [@B51]; [@B75]; [@B6]) and may be considered an anomaly of cell differentiation. This observation has prompted researchers to investigate the role of the canonical Wnt signaling and the Hippo pathway, two molecular pathways known to regulate embryonic development and adult tissue homeostasis, on the development of fibroadiposis in both conditions.

Wnt Signaling in ACM and SMD {#S1.SS5}
----------------------------

The Wnt signaling network controls embryonic development and adult tissue homeostasis, through the regulation of proliferation, cell polarity and migration, and cell fate specification ([@B67]). It includes three highly conserved signaling pathways: the canonical β-catenin-dependent Wnt pathway and the two non-canonical β-catenin independent pathways (the non-canonical Wnt planar cell polarity and the non-canonical Wnt/calcium pathways) ([@B67]). Wnt ligands are a family of secreted glycoproteins with autocrine and paracrine functions ([@B67]).

Canonical and non-canonical Wnt pathways are known to compete between each other; the predominance of a pathway over the other depends on the expression of specific Wnt ligands and cell-surface receptors \[Frizzled receptors (Fzd)\] and coreceptors in a given cell or tissue, at a given time point ([@B46]; [@B80]).

β-Catenin is the main effector of the canonical Wnt signaling ([@B46]). In the absence of Wnt signals, β-catenin is incorporated in the so-called destruction complex where β-catenin is phosphorylated by the glycogen synthase kinase 3-beta (GSK3β) and degraded ([@B46]). Upon Wnt binding to Fzd receptors and the coreceptor Lrp5/6, the components of the destruction complex are recruited to the plasma membrane preventing the degradation of β-catenin that translocates to the nucleus and binds the TCF/LEF transcription factor ([@B81]; [@B80]).

Suppression of the canonical Wnt/β-catenin signaling is known to provoke adipogenesis, fibrogenesis, and apoptosis ([@B120]; [@B24]; [@B77]).

We have identified suppression of the canonical Wnt signaling as an important mechanism for the enhanced adipogenesis in desmosomal ACM ([@B41]; [@B75]; [@B73]; [@B25]). We showed that mutations in desmosome genes alter assembly of the desmosomes and cause partial relocalization of JUP to the nucleus where it competes with β-catenin for binding to the transcription factor TCF/LEF, resulting in suppression of the canonical Wnt signaling ([@B41]; [@B73]), which in turn determines a switch from myogenesis to adipogenesis in cardiac progenitors ([@B74], [@B73]).

Inhibition of canonical Wnt signaling because of the activation of GSK3β and increased degradation of β-catenin has been also shown in a non-desmosomal form of ACM caused by a *TMEM43* mutation ([@B104]). Another study in an ACM transgenic mouse model with cardiomyocyte-specific overexpression of a FLAG-tagged human desmoglein-2 harboring the Q558^∗^ nonsense mutation has confirmed inhibition of Wnt signaling in the pathogenesis of the disease ([@B17]). Moreover, a zebrafish model of DSP deficiency has been recently generated for *in vivo* cell signaling screen, using pathway-specific reporter transgenes. Out of nine considered, three pathways (Wnt/β-catenin, TGFβ/Smad3, and Hippo/YAP-TAZ) were significantly altered, with Wnt as the most dramatically affected ([@B45]). The findings of all these papers point to Wnt/β-catenin as the final common pathway underlying the ACM pathogenesis, independently from the causal gene. The role of the nuclear translocation of plakoglobin as the main mechanism for the inhibition of Wnt signaling in ACM is still uncertain. A paper on a mouse model with cardiac-specific deletion of JUP showed that despite the model largely recapitulated the phenotype of human ACM, the Wnt/β-catenin-mediated signaling was not altered, while transforming growth factor-beta-mediated signaling was found significantly elevated ([@B69]). Furthermore, a 2009 paper reported that endomyocardial biopsies from patients with ACM, but not controls, present with a marked reduction in immune-reactive signal levels for plakoglobin, suggesting that routine immunohistochemical analysis for plakoglobin expression of conventional endomyocardial biopsy samples could be a highly sensitive and specific diagnostic test for ACM ([@B4]). However, later on, subsequent studies revealed that plakoglobin-signal reduction was not a sensitive ([@B34]) nor a specific diagnostic marker for ACM, as it could also be demonstrated in other cardiac diseases, such as in sarcoidosis and giant-cell myocarditis ([@B3]).

Published data on the impact of Wnt signaling in the pathogenesis of muscular dystrophies have been conflicting. Increased β-catenin/Tcf transcriptional activity has been detected in the circulation, along with increased protein levels of β-catenin and enhanced DNA-binding activity of β-catenin/TCF in the skeletal muscle of DMD patients, suggestive of negative effects of activation of the canonical Wnt signaling pathway in DMD ([@B71]). On the contrary, activation of the canonical Wnt signaling pathway by intramuscular injection of Wnt3a in mdx mice has been proven to be beneficial as it attenuated the dystrophic phenotype ([@B127]). The inconsistence of these reports is most likely due to differences in the timing in which the Wnt signaling was assessed with regard to the state of cellular differentiation or to the interaction with other signaling pathways.

Hippo Signaling in ACM and SMD {#S1.SS6}
------------------------------

The Hippo signaling is an evolutionally conserved pathway consisting of a cascade of serine/threonine kinases: the tumor suppressor Hippo (MST1/2), large tumor suppressor kinases 1/2 (LATS1/2), and Yes-associated protein (YAP) ([@B105]; [@B53]). YAP, the effector of Hippo pathway, is negatively regulated by phosphorylation by its upstream kinases. Non-phosphorylated/active YAP migrates to the nucleus, where it interacts with TEA domain family member (TEAD) transcription factor and regulates cell fate, muscle growth, regeneration, and wasting ([@B105]; [@B53]; [@B163]). So far, only limited studies have explored the relationship between the Hippo pathway and the pathogenesis of ACM or muscular dystrophies.

A study from our group in human hearts with ACM and two independent mouse and cell culture ACM models identified activation of the Hippo pathway as a major mechanism in the pathogenesis of ACM ([@B25]). We showed that, in ACM, mutations in genes encoding desmosome proteins, by impairing cell--cell attachment, activate neurofibromin 2 (NF2), the upstream molecule of the Hippo pathway. Active NF2 initiates the cascade of the Hippo kinases downstream to NF2, which culminates in YAP phosphorylation/inactivation. As a result, gene expression through TEAD is suppressed ([@B25]). In addition, we showed that activation of the Hippo pathway contributes to suppress the canonical Wnt signaling as phosphorylated YAP sequestrates β-catenin in the cytosol, preventing its translocation into the nucleus ([@B25]). Collectively, these findings provide a mechanistic link between the mutant desmosome protein and enhanced adipogenesis through the Hippo and the canonical Wnt signaling pathways in ACM. Activation of Hippo/YAP-TAZ in the pathogenesis of ACM has also been confirmed by a recent study on a novel zebrafish model of DSP deficiency ([@B45]).

In the skeletal muscle, YAP has a major role in myoblast proliferation, atrophy/hypertrophy, and mechanotransduction ([@B61]; [@B157]; [@B39]).

A reduction in active YAP protein expression and increased LATS1/2 kinase activity has been found in skeletal muscle specimens from DMD patients but not in muscles from patients with other types of muscular dystrophy ([@B155]). However, these results from DMD patients have not been completely reproduced in mdx mice in which, although the increase in LATS1/2 activity was confirmed, the levels of total YAP and phosphorylated YAP were found to be elevated or not changed ([@B155]). The findings suggest that activation of Hippo is implicated in the pathogenesis of DMD, but the specific functions of key molecular regulators remain largely unknown.

A recent paper has shown that, in cardiac myocytes, dystroglycan 1 (DAG1), a component of the DGC, directly binds to YAP and inhibits cardiomyocyte proliferation; moreover, Hippo-induced YAP phosphorylation promotes YAP--DAG1 interaction, suggesting cooperation between Hippo pathway and DGC in preventing the nuclear localization of YAP ([@B95]). In the same paper, the authors show that, in the absence of dystrophin (like in DMD), the interaction of YAP with DGC is disrupted ([@B95]); however, the mechanism through which phosphorylated YAP is sequestered to the cell membrane in the absence of dystrophin and sarcoglycan-δ is not identified.

Membrane Channels and Calcium Signaling in ACM and SMD {#S1.SS7}
------------------------------------------------------

Several studies suggest dysregulation of ion channels and of the Ca^2+^ signaling machinery in ACM, not only as direct effect of causal mutations located in genes encoding components of the Ca^2+^ cycling machinery (such as PLN) but also as a consequence of mutations in desmosomal genes ([@B99]).

*In vitro* and *in vivo* studies have shown that decreased expression of PKP2 and DSP in cardiomyocytes affects expression levels, phosphorylation, and function of connexin 40 and connexin 43 independently of the cell--cell detachment and prior to the fibrofatty infiltration of the myocardium ([@B103]; [@B99]; [@B79]). Additionally, mutations in desmosomal proteins have been shown to affect the sodium channel function prior to cardiomyopathic changes ([@B122]; [@B119]; [@B20]). These data suggest a role for desmosomal proteins as stabilizers of the gap junction integrity and highlight the molecular mechanisms of early electrical defects found in ACM patients.

ACM causal mutations in the non-desmosomal gene encoding PLN directly impair the calcium handling machinery ([@B146]; [@B147]). On the other hand, recent studies in induced pluripotent stem cell-derived cardiomyocytes (hIPSC-CMs) and mouse models have shown that cardiomyocyte PKP2 deficiency causes calcium handling dysregulation by affecting the transcription of genes and the function of components of intracellular calcium cycling machinery ([@B63]; [@B21]; [@B65]).

Abnormal calcium homeostasis has also been described in the pathogenesis of cardiac disease in the course of dystrophinopathies ([@B158]; [@B159]; [@B36]). The absence of dystrophin in the heart renders cardiomyocytes more sensitive to stretch-induced damage leading to loss of plasma membrane integrity, which results in an increased calcium influx into the cell ([@B160]; [@B161]; [@B158]; [@B159]; [@B36]). Elevation in intracellular Ca^2+^ has several negative effects: mitochondrial deregulation, induction of protease calpain-mediated necrosis, activation of Ca^2+^/calmodulin (CaM) and CaM kinase II (CaMKII) and protein kinase A (PKA), and activation of nuclear factor kappa B (NF-κB) and of neuronal nitric oxide synthase (nNOS) ([@B161]; [@B158]; [@B159]; [@B36]). The resulting cell damage causes degeneration of the cardiomyocytes and fibrosis, which are responsible of development of dilated cardiomyopathy.

Cell Origin of Fibroadiposis in ACM and SMD {#S1.SS8}
-------------------------------------------

Skeletal muscle consists of fascicles of elongated multinucleate cells, called myofibers, while the myocardium is composed of single binucleate cardiomyocytes connected through the intercalated disks, unique structures that enable them to work as a single functional syncytium. Both adult skeletal and cardiac muscle cells do not divide; however, while skeletal muscle is able to have a considerable amount of regeneration, cardiac myocytes have a limited regeneration capacity after injury.

Upon skeletal muscle injury, satellite cells (SCs) promptly re-enter the cell-cycle, proliferate and differentiate in order to repair the damaged myofibers, and, at the same time, repopulate the SC reserve pool by self-renewing ([@B37]). On the other hand, myocyte death due to chronic cardiac injury is not followed by replacement with new cardiomyocytes but results in activation of the extracellular matrix and consequent fibrosis.

Genetic mutations in ACM and in SMD cause persistent muscle damage; the resulting progressive-chronic injury induces abnormal tissue repair ending in fibroadiposis.

In the skeletal muscle, effective repair requires functional crosstalk of SCs with other resident cell types including motor neurons, endothelial cells, immune cells, fibrogenic cells, and adipogenic precursors ([@B134]; [@B143], [@B144]; [@B56]; [@B152]). Among them, mesenchymal progenitors identified by the surface marker PDGFRA have recently emerged as important players in skeletal muscle regeneration, but they have also been identified as the main source of intramuscular fibro/adipogenesis in pathological conditions ([@B60]; [@B143], [@B144]). PDGFRα + cells are also known as fibroadipocyte progenitors (FAPs) because of their fibrogenic and adipogenic potential ([@B143], [@B144]). Upon acute muscle injury, FAPs are activated and, in normal conditions, act in synergy with SCs to promote efficient muscle regeneration ([@B60]; [@B143], [@B144]; [@B56]). In contrast, when the muscle injury is persistent, like in muscular dystrophies, activated FAPs differentiate to fibroblasts and adipocytes ([@B60]; [@B143], [@B144]; [@B56]).

In ACM, the cell source of adipocytes has been an enigma for many years. Recently, our group has shown that cardiac progenitor cells (CPCs) from the second heart field are a source of adipocytes in ACM ([@B74], [@B73]; [@B75], [@B76]); however, these cells are rare in the heart and account for only a small fraction of the adipocytes. Thus, cardiac cells other than CPCs might contribute to fibroadiposis in ACM.

Since ACM and SMD show similar fibroadipocytic replacement of muscle, we surmised that the heart, like skeletal muscle, might contain resident FAPs, which could differentiate to adipocytes in the presence of chronic injury due to the presence of mutant desmosomal proteins. Therefore, we isolated from human and mouse heart a population of progenitor cells, positive for PDGFRA and negative for other lineage and fibroblast markers, which we named cardiac FAPs ([@B72]). Cardiac FAPs express desmosomal proteins (which are encoded by most of ACM causal genes) and are bipotential as the majority express the fibroblast marker collagen 1 α-1, while a small subset expresses the adipogenic marker CCAAT/enhancer-binding protein α ([@B72]). *In vivo* genetic fate-mapping experiments demonstrated ∼40% of adipocytes in the heart of a mouse model of ACM originates from FAPs, through a Wnt-dependent mechanism ([@B72]). The findings expand the cellular spectrum of ACM, commonly recognized as a disease of cardiomyocytes, to include non-myocyte cells in the heart.

Conclusion {#S2}
==========

Arrhythmogenic cardiomyopathy and SMDs share many histological and molecular/cellular pathogenic mechanisms; for this reason, research findings from either pathology are expected to have significant reciprocal impact. Muscle degeneration, inflammation, and fibroadipocytic replacement have been described, and common molecular pathways (such as Wnt and Hippo signaling) and cell types have been shown to play a pathogenic role in both diseases. Moreover autoimmunity is an emerging research area with important translational promises for the clinical management and treatment of affected individual in both conditions.

In this review, we summarize for the first time the analogies between studies on skeletal muscle dystrophies and arrhythmogenic cardiomyopathy, with a particular focus on the findings with the highest potential for knowledge exchange between the two research fields.
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